PRESS RELEASE NORTH CHICAGO, Ill.andSUNNYVALE, Calif fda website .,March 4, 2015/PRNewswire/ –AbbVie and Pharmacyclics today announced a definitive contract under which AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica® , a highly effective treatment for hematologic malignancies. The acquisition accelerates AbbVie's clinical and commercial presence in oncology, strengthening its robust pipeline already, and establishing its strong leadership placement in hematological oncology – an attractive and quickly growing market, now approaching$24billionglobally. The acquisition increases AbbVie's in depth pipeline and solid growth prospects already.
Boehringer Ingelheim shall produce ficlatuzumab for scientific trials at its biopharmaceutical site in Fremont, USA. AVEO retains all rights to the advancement and commercialization of ficlatuzumab. Financial conditions of the agreement weren’t disclosed. This agreement is further proof the progress we are making in the clinical development of ficlatuzumab, and we anticipate working with Boehringer Ingelheim to prepare for the manufacturing actions for ficlatuzumab that would support Stage 3 and beyond. Frank Ternes, senior vice president of the Contract Production Business Biopharmaceuticals at Boehringer Ingelheim, commented, We are delighted to be selected by AVEO as a making partner for ficlatuzumab and we anticipate leveraging our a lot more than 25 years knowledge in this region to aid AVEO in further executing its clinical development approaches for ficlatuzumab.